Your email has been successfully added to our mailing list.

×
0.00206611570247948 0.00206611570247948 -0.00413223140495859 -0.00413223140495859 -0.018595041322314 -0.0640289256198347 -0.0392561983471073 -0.0247933884297519
Stock impact report

Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (CATB) 
Last catabasis pharmaceuticals, inc. earnings: 3/10 08:05 am Check Earnings Report
US:NASDAQ Investor Relations: ir.catabasis.com/investor-overview
Company Research Source: Business Wire
-- Differentiating Safety and Tolerability Profile of Edasalonexent Through More Than 55 Patient Years of Exposure -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented the findings from the MoveDMD trial of edasalonexent. In the Phase 2 MoveDMD trial and open-label extension, edasalonexent slowed disease progression compared to the off-treatment control period and was well tolerated through more than 55 cumulative patient years of exposure in boys affected by Duchenne muscular dystrophy (DMD). These data were presented by Dr. Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatrics at Nemours Children’s Health System, and Principal Investigator for the Phase 2 MoveDMD and Phase 3 PolarisDMD studies of edasalonexent in DMD at the 24th International Annual Congress of the World Muscle Society.“Our goal is to provide a therapy for DMD that slows disease progression, has a co Show less Read more
Impact Snapshot
Event Time:
CATB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CATB alerts
Opt-in for
CATB alerts

from News Quantified
Opt-in for
CATB alerts

from News Quantified